The Research and Health Foundation led a preliminary analysis to understand how drugs are cited and what their weight is within the current diagnostic-therapeutic care pathways (PDTA) referring to chronic diseases. The results highlight the need to provide for the specification of which drugs to use and the related methods of use. The issue is also important due to the connection between specific decisions of the Italian Medicines Agency concerning the access and reimbursement of the drug and their use.